Table 4.
Inhibitory efficacy of a type I IFN pre-treatment on Vero/CD150 cells before MV infection
| Concentration of IFN added (IU/mL) | ||||||
| Time before infection | Strain | 5000 | 1000 | 500 | 100 | 0 |
| 8 h | G954-PBL | 100* | 92 | 95 | 63 | 0 |
| G954-V13 | 100 | 95 | 89 | 56 | 0 | |
| Ed-Zagreb | 100 | 79 | 65 | 58 | 0 | |
| 24 h | G954-PBL | 100 | 100 | 100 | 95 | 0 |
| G954-V13 | 100 | 100 | 100 | 67 | 0 | |
| Ed-Zagreb | 100 | 100 | 100 | 43 | 0 | |
| 48 h | G954-PBL | 100 | 100 | 100 | 91 | 0 |
| G954-V13 | 100 | 100 | 100 | 80 | 0 | |
| Ed-Zagreb | 100 | 100 | 100 | 81 | 0 | |
* Inhibition indices were calculated as follow: 100 × [1 – (PFU(type I IFN = x)/PFU(type I IFN = 0)]